CHEERWIN GP (06601) has completed the acquisition of 100% equity of Hebei Kangda.

06:41 26/01/2026

Chao Yun Group (06601) announced that all conditions specified in the agreement have been met. The industrial and commercial change registration of the acquisition and the acquisition itself were completed on January 23, 2026. Upon completion, the target company Hebei Kangda Co., Ltd. will become the Company's indirect wholly-owned subsidiary, and the financial performance of the target group will be consolidated into the Group's financial statements.

CHEERWIN GP (06601) announces that all conditions stated in the agreement have been met. The industrial and commercial registration changes related to the acquisition were completed on January 23, 2026. Following the completion, the target company Hebei Kanda Co., Ltd. will become the company's indirect wholly-owned subsidiary, and the financial performance of the target group will be consolidated into the group's financial statements.

ASCLETIS-B (01672) announced that the first batch of subjects in the 13-week Phase II study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes has been dosed in the United States.

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.

Revenue exceeds expectations with a 30% growth, profit validation of "AI + chronic disease service" mode. What did this company, which does not compete for traffic, do right?

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.

Revenue exceeds expectations with a 30% growth, profit validation of "AI + chronic disease service" mode. What did this company, which does not compete for traffic, do right?